Abbott Laboratories (ABT): Politician trade (House)

$1,001–$15,000
Reported range · official band, not an exact amount: 27 days
Disclosure lag

Traded: Jun 12, 2026
Disclosed: Jul 9, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Mar 27, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
Apr 16, 2026Company filing · Form 8-K · ResultsReported its results
Apr 16, 2026FDAFDA device clearance: Disposable Radiofrequency Cannula
Apr 16, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
Apr 20, 2026FDAFDA device clearance: EnSite X EP System
Apr 23, 2026Insider · 1 day before an 8-KCFO purchased ~$201K of ABT shares in the open market
Apr 24, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders.”
Apr 24, 2026FDAFDA device clearance: OPTIS Mobile Next Imaging System (1014932); OPTIS Integrated Next Imaging System (1014933); Ultreon 3.0 Software Upgrade Kit (ULTR300001)
Apr 24, 2026FDAFDA device clearance: Amplatzer TorqVue Delivery System
Apr 27, 2026Insider · Their largest buy since 2018Director purchased ~$927K of ABT shares in the open market
Apr 28, 2026FDAFDA device clearance: Anti-HCV Next
Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
May 7, 2026Insider · Their largest buy since 2019Director purchased ~$174K of ABT shares in the open market
May 12, 2026FDARecall: Merlin" Patient Care System (PCS) software Merlin" PCS 3650 programmer Model 3330 software
May 12, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
May 15, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
May 27, 2026Government · Federal Register noticeDrugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661
May 27, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
Jun 12, 2026 · this disclosureCongressDisclosed purchase of ABT — reported range $1,001 - $15,000

What came next

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Abbott Laboratories

For Abbott Laboratories, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 82 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.

Other recent filings by Rep. Richard Dean Dr McCormick (GA06)

The full history of Rep. Richard Dean Dr McCormick (GA06) is on the profile page.

Other disclosures at Abbott Laboratories

Everything OQRO holds on this company is on its ABT page.

Abbott Laboratories (ABT)Rep. Richard Dean Dr McCormick (GA06) disclosed a purchase $1K–$15K